Fundraising Fox

Entrada Therapeutics, Inc.

NASDAQ: TRDA

Boston, US · Founded 2016 · Delaware corporation · 6 known investors

entradatx.com ↗

Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.

BiotechHealthtechMedical Devicesin /entradatx

Founders & leadership

CN
Carole NuechterleinDirector
NS
Natarajan SethuramanExecutive Officer
KMKush M. Parmar
Kush M. ParmarinDirector
TF
Todd FoleyDirector
PK
Peter KimDirector
NK
Nerissa KreherExecutive Officer
KW
Kory WentworthExecutive Officer
DDDipal Doshi
Dipal DoshiinExecutive Officer, Director
JF
John F. CrowleyDirector
ND
Nathan DowdenExecutive Officer

Investors · 6

MPM BioImpactBoston · $1M – $15Mvia Todd Foley · board
MPM Capital
Roche Venture FundBasel · $648K – $3.2M
TCG CrossoverPalo Alto
5AM VenturesreportedBoston · $100K – $4Mvia Kush M Parmar · board
Agent CapitalreportedWaltham

Reported raises · per SEC filings

Form D private placements
▶$116.2MraisedApr 2021 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carole NuechterleinDirector
  • Natarajan SethuramanExecutive Officer
  • Kush M. ParmarDirector
  • Todd FoleyDirector
  • Peter KimDirector
  • Nerissa KreherExecutive Officer
  • Kory WentworthExecutive Officer
  • Dipal DoshiExecutive Officer, Director
  • John F. CrowleyDirector
  • Nathan DowdenExecutive Officer
Offering amount
$116.2M
Amount sold
$116.2M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$34MraisedDec 2019 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Natarajan SethuramanExecutive Officer
  • John CrowleyDirector
  • Nathan DowdenExecutive Officer
  • Louis TartagliaDirector
  • Kush ParmarDirector
  • Christine BrennanDirector
  • Anja HarmeierDirector
  • Dipal DoshiExecutive Officer, Director
  • Todd FoleyDirector
  • Mario SaltarelliExecutive Officer
Offering amount
$59M
Amount sold
$34M
Proceeds to insiders
$3.4M
First sale
Dec 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$600KraisedNov 2016 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kush ParmarExecutive Officer, Director
  • Louis TartagliaExecutive Officer, Director
  • Dehua PeiDirector
Offering amount
$1.6M
Amount sold
$600K
First sale
Oct 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news